Don't Buy Third Harmonic (THRD) Without Checking Its Fundamentals!

Healthcare sector company Third Harmonic posted a -0.9% performance today, while the S&P 500 returned 0.1%.

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. The company is based in Cambridge and has 22 full time employees. Its market capitalization is $170,693,609.54666138.

3 analysts are following Third Harmonic and have set target prices ranging from $3.6 to $39 per share. On average, they have given the company a rating of buy. At today's prices, THRD is trading -73.47% away from its average analyst target price of $15.87 per share.

Over the last year, THRD shares have gone down by -75.0%, which represents a difference of -66.6% when compared to the S&P 500. The stock's 52 week high is $24.59 per share and its 52 week low is $3.89. Third Harmonic has averaged free cash flows of $-12,466,500.0 over the last four years, with a mean growth rate of -71.4%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.

Date Reported Cash Flow from Operations ($ MM) Capital expenditures ($ MM) Free Cash Flow ($ MM) YoY Growth (%)
2021-12-31 -16 n/a -16 -71.39
2020-12-31 -9 n/a -9 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.